Lexaria Biosciences Corp (NASDAQ:LEXX) has announced that its Amari Corp’s “everyday calm” CBD has been named a Top CBD Product Pick by New Hope Network, a top Natural Products Expo conference events host. Several CBD products were competing for the “Top Picks for 2020 of New Hope Network editors.”
DehydraTECH™ tech growing in popularity
Amari CEO Eric Gricus said that the company went through an intense selection process for its CBD tech supplier. He said that Lexaria exceeded the expectations in service, product quality, and pricing. Gricus added that they are delighted to be working with the Lexaria team to help develop products that customers love and win accolades in the industry.
Lexaria’s DehydraTECH™ tech is efficient and quick in delivering CBD to meet consumer satisfaction and enhanced brand loyalty. Chris Bunka, Lexaria’s CEO, said that they are delighted to work with Amaria on their award-winning products. He said that the DehydraTECH™ technology is gaining growing consumer support, and they expect to have more products leveraging the tech in stores across America.
Lexaria exploring new drug markets
The company is planning to commence new applied R&D studies this year in additional drug markets. Lexaria’s new programs will target four-drug markets that include NSAIDs, tetrahydrocannabinol, nicotine replacement therapies, and erectile dysfunction. The study programs will evaluate absorption rate and pharmacokinetics with which different enhanced DehydraTECH™ investigational formulations deliver drugs into the bloodstream and the brain in some cases after oral dosing. The studies will also demonstrate evidence of delivery efficiency improvements and reduced time taken to deliver the experimental drugs into the brain and bloodstream. This will support additional studies and commercialization through pharmaceutical industry strategic partnerships.
Bunka said that their 2021 study program is the largest in its history and has grown considerably. He said that their studies have been designed to generate important data that will allow the company to have meaningful business discussions with different industry leaders and shorten the required time for positive commercial developments.